Capvaxvie

Phase 3Biologic

UUniversity of Alabama at Birmingham

Capvaxvie is one of 6 biologic programs targeting Homeostasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HomeostasisRecruiting

HomeostasisPhase 3

Recruiting

Competition

Competitive Landscape

6 competitors in Homeostasis

#DrugCompanyPhaseTrials

Glucophage

EMD Serono

Approved

1 2

JYNNEOS

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 3

1 3

Isonep

JJiangsu Nhwa Pharmaceutical Co., Ltd.

Phase 3

1 4

Capvaxvie

UUniversity of Alabama at Birmingham

Phase 3

1 5

Leptin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 6

Aldosterone

YYale University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Post-ApprovalRecruiting

Homeostasis

NCT06829238

Clinical

Trials by Indication[1]

Homeostasis1 trial

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use

Recruiting·UUniversity of Alabama at Birmingham·Phase 4·NCT06829238·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Capvaxvie. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Capvaxvie compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Capvaxvie. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Alabama at Birmingham company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Alabama at Birmingham

Capvaxvie

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Homeostasis1 trial

References

Drug Info

Quick Facts

Related News